Chairman
Current
Greater New York City Area
Harrison Hayes is defined by two practices. We manage a family of Venture Funds including BioArbitrage Funds I, II and III and The Orphanetics Rare Disease Innovation Fund. Our consulting practice intersects the dynamics of creative product development, innovation research, and intellectual property identification. Our capabilities include: · Define new growth sectors· Expand existing technologies and assets to unlock new value· Develop and launch new products, brands & businesses within identified strategic areas;· Stimulate acquisitions with innovation, and innovation with acquisitions;· Expand products, brands and companies into new segments, categories or businesses;· Turn around problem brands and businesses through dynamic innovation. We maintain alliances with select members of biotechnology, pharmaceutical, medical device, drug delivery and supporting sectors of the industry. Our tailored focus places our offerings far above those of traditional multi-industry consulting firms and allows us to operate within a timeframe that exceeds our clients' expectations. We know the life sciences industry like know one else, armed with a skilled team of analysts and consultants from the medical, scientific, research, marketing and business development communities.Successes: Responsible for the Ideation Development Initiative that led to the creation of the Xience stent (now marketed by Abbott Labs); Identification of Requip for a new RLS indication; Whitespace Innovation project leading to the development of Sular (now marketed by Shionogi); Other client ideation work leading to commercialization include Chiesi, Pliva, Encentify Pharma, Libbs, Avimex, Astra Zeneca, Medtronic and Johnson & Johnson.
